Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis

Inflamm Bowel Dis. 2021 Oct 18;27(10):1694-1697. doi: 10.1093/ibd/izab097.
No abstract available

Keywords: biologic therapy; clinical remission; comparative effectiveness; inflammatory bowel disease; ulcerative colitis.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Colitis, Ulcerative* / drug therapy
  • Humans
  • Piperidines / chemistry
  • Piperidines / pharmacology
  • Propensity Score
  • Pyrimidines / pharmacology
  • Treatment Outcome
  • Ustekinumab*

Substances

  • Piperidines
  • Pyrimidines
  • tofacitinib
  • Ustekinumab